Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 12/2018

01.08.2018 | Review Article

Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option

verfasst von: Mellar P. Davis, Gavril Pasternak, Bertrand Behm

Erschienen in: Drugs | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

The buprenorphine receptor binding profile is unique in that it binds to all three major opioid receptors (mu, kappa, delta), and also binds to the orphan-like receptor, the receptor for orphanin FQ/nociceptin, with lower affinity. Within the mu receptor group, buprenorphine analgesia in rodents is dependent on the recently discovered arylepoxamide receptor target in brain, which involves a truncated 6-transmembrane mu receptor gene protein, distinguishing itself from morphine and most other mu opioids. Although originally designed as an analgesic, buprenorphine has mainly been used for opioid maintenance therapy and only now is increasingly recognized as an effective analgesic with an improved therapeutic index relative to certain potent opioids. Albeit a second-, third-, or fourth-line analgesic, buprenorphine is a reasonable choice in certain clinical situations. Transdermal patches and buccal film formulations are now commercially available as analgesics. This review discusses buprenorphine pharmacodynamics and pharmacokinetics, use in certain populations, and provides a synopsis of systematic reviews and randomized analgesic trials. We briefly discuss postoperative management in patients receiving buprenorphine maintenance therapy, opioid equivalence to buprenorphine, rotations to buprenorphine from other opioids, and clinical relevance of buprenorphine-related QTc interval changes.
Literatur
1.
Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012;10(6):209–19.PubMedCrossRef
2.
Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry. 1978;35(4):501–16.PubMedCrossRef
3.
Henningfield JE, Sun WZ. Concluding statement—neuropharmacological basis and clinical rationale for control of transdermal buprenorphine as a step II analgesic. Acta Anaesthesiol Taiwan. 2015;53(2):77–9.PubMedCrossRef
4.
Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96(5):627–32.PubMedCrossRef
5.
Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005;94(6):825–34.PubMedCrossRef
6.
Pergolizzi JV Jr, Scholten W, Smith KJ, Leighton-Scott J, Willis JC, Henningfield JE. The unique role of transdermal buprenorphine in the global chronic pain epidemic. Acta Anaesthesiol Taiwan. 2015;53(2):71–6.PubMedCrossRef
7.
Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Sympt Manag. 2005;29(3):297–326.CrossRef
8.
Ding Z, Raffa RB. Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. Br J Pharmacol. 2009;157(5):831–43.PubMedPubMedCentralCrossRef
9.
Khroyan TV, Wu J, Polgar WE, Cami-Kobeci G, Fotaki N, Husbands SM, et al. BU08073 a buprenorphine analogue with partial agonist activity at mu-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice. Br J Pharmacol. 2015;172(2):668–80.PubMedCrossRef
10.
11.
Negus SS, Bidlack JM, Mello NK, Furness MS, Rice KC, Brandt MR. Delta opioid antagonist effects of buprenorphine in rhesus monkeys. Behav Pharmacol. 2002;13(7):557–70.PubMedCrossRef
12.
Grinnell SG, Ansonoff M, Marrone GF, Lu Z, Narayan A, Xu J, et al. Mediation of buprenorphine analgesia by a combination of traditional and truncated mu opioid receptor splice variants. Synapse. 2016;70(10):395–407.PubMedPubMedCentralCrossRef
13.
Majumdar S, Grinnell S, Le Rouzic V, Burgman M, Polikar L, Ansonoff M, et al. Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. Proc Natl Acad Sci USA. 2011;108(49):19778–83.PubMedCrossRef
14.
Traynor JR, Nahorski SR. Modulation by mu-opioid agonists of guanosine-5′-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol. 1995;47(4):848–54.PubMed
15.
Fantozzi R, Mullikin-Kilpatrick D, Blume AJ. Irreversible inactivation of the opiate receptors in the neuroblastoma x glioma hybrid NG108-15 by chlornaltrexamine. Mol Pharmacol. 1981;20(1):8–15.PubMed
16.
Zaki PA, Keith DE Jr, Brine GA, Carroll FI, Evans CJ. Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation? J Pharmacol Exp Ther. 2000;292(3):1127–34.PubMed
17.
McPherson J, Rivero G, Baptist M, Llorente J, Al-Sabah S, Krasel C, et al. mu-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol. 2010;78(4):756–66.PubMedPubMedCentralCrossRef
18.
Vanderah TW, Gardell LR, Burgess SE, Ibrahim M, Dogrul A, Zhong CM, et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci. 2000;20(18):7074–9.PubMedCrossRef
19.
Ossipov MH, Lai J, Malan TP Jr, Porreca F. Spinal and supraspinal mechanisms of neuropathic pain. Ann N Y Acad Sci. 2000;909:12–24.PubMedCrossRef
20.
Stanciu CN, Glass OM, Penders TM. Use of Buprenorphine in treatment of refractory depression: a review of current literature. Asian J Psychiatr. 2017;26:94–8.PubMedCrossRef
21.
Karp JF, Butters MA, Begley AE, Miller MD, Lenze EJ, Blumberger DM, et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75(8):e785–93.PubMedPubMedCentralCrossRef
22.
Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15(1):49–57.PubMedCrossRef
23.
Falcon E, Browne CA, Leon RM, Fleites VC, Sweeney R, Kirby LG, et al. Antidepressant-like effects of buprenorphine are mediated by kappa opioid receptors. Neuropsychopharmacology. 2016;41(9):2344–51.PubMedPubMedCentralCrossRef
24.
Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science. 1999;286(5449):2495–8.PubMedCrossRef
25.
Raehal KM, Schmid CL, Groer CE, Bohn LM. Functional selectivity at the mu-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev. 2011;63(4):1001–19.PubMedPubMedCentralCrossRef
26.
Raehal KM, Bohn LM. The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology. 2011;60(1):58–65.PubMedCrossRef
27.
Reiter E, Ahn S, Shukla AK, Lefkowitz RJ. Molecular mechanism of beta-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol. 2012;52:179–97.PubMedCrossRef
28.
Yu Y, Zhang L, Yin X, Sun H, Uhl GR, Wang JB. Mu opioid receptor phosphorylation, desensitization, and ligand efficacy. J Biol Chem. 1997;272(46):28869–74.PubMedCrossRef
29.
Grinnell SG, Majumdar S, Narayan A, Le Rouzic V, Ansonoff M, Pintar JE, et al. Pharmacologic characterization in the rat of a potent analgesic lacking respiratory depression, IBNtxA. J Pharmacol Exp Ther. 2014;350(3):710–8.PubMedPubMedCentralCrossRef
30.
31.
Cowan A. Buprenorphine: new pharmacological aspects. Int J Clin Pract Suppl. 2003;133:3–8 (discussion 23–4).
32.
Kogel B, Christoph T, Strassburger W, Friderichs E. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Eur J Pain. 2005;9(5):599–611.PubMedCrossRef
33.
Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain. 2009;13(3):219–30.PubMedCrossRef
34.
Recker MD, Higgins GA. The opioid receptor like-1 receptor agonist Ro 64-6198 (1S,3aS-8-2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one) produces a discriminative stimulus in rats distinct from that of a mu, kappa, and delta opioid receptor agonist cue. J Pharmacol Exp Ther. 2004;311(2):652–8.PubMedCrossRef
35.
Lewis JW, Husbands SM. The orvinols and related opioids–high affinity ligands with diverse efficacy profiles. Curr Pharm Des. 2004;10(7):717–32.PubMedCrossRef
36.
Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10(5):428–50.PubMedCrossRef
37.
Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med. 2006;20(Suppl 1):s3–8.PubMed
38.
Gerhold KJ, Drdla-Schutting R, Honsek SD, Forsthuber L, Sandkuhler J. Pronociceptive and antinociceptive effects of buprenorphine in the spinal cord dorsal horn cover a dose range of four orders of magnitude. J Neurosci. 2015;35(26):9580–94.PubMedPubMedCentralCrossRef
39.
Schnabel A, Reichl SU, Zahn PK, Pogatzki-Zahn EM, Meyer-Friessem CH. Efficacy and safety of buprenorphine in peripheral nerve blocks: a meta-analysis of randomised controlled trials. Eur J Anaesthesiol. 2017;34(9):576–86.PubMedCrossRef
40.
Leffler A, Frank G, Kistner K, Niedermirtl F, Koppert W, Reeh PW, et al. Local anesthetic-like inhibition of voltage-gated Na(+) channels by the partial mu-opioid receptor agonist buprenorphine. Anesthesiology. 2012;116(6):1335–46.PubMedCrossRef
41.
Rickli A, Liakoni E, Hoener MC, Liechti ME. Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. Br J Pharmacol. 2018;175(3):532–43.PubMedPubMedCentralCrossRef
42.
Sutcliffe KJ, Henderson G, Kelly E, Sessions RB. Drug binding poses relate structure with efficacy in the mu opioid receptor. J Mol Biol. 2017;429(12):1840–51.PubMedPubMedCentralCrossRef
43.
Christopoulos A, El-Fakahany EE. Qualitative and quantitative assessment of relative agonist efficacy. Biochem Pharmacol. 1999;58(5):735–48.PubMedCrossRef
44.
Heit HA, Gourlay DL. Buprenorphine: new tricks with an old molecule for pain management. Clin J Pain. 2008;24(2):93–7.PubMedCrossRef
45.
46.
Macintyre PE, Huxtable CA. Buprenorphine for the management of acute pain. Anaesth Intensive Care. 2017;45(2):143–6.PubMed
47.
Macintyre PE, Russell RA, Usher KA, Gaughwin M, Huxtable CA. Pain relief and opioid requirements in the first 24 hours after surgery in patients taking buprenorphine and methadone opioid substitution therapy. Anaesth Intensive Care. 2013;41(2):222–30.PubMed
48.
Huxtable CA, Roberts LJ, Somogyi AA, MacIntyre PE. Acute pain management in opioid-tolerant patients: a growing challenge. Anaesth Intensive Care. 2011;39(5):804–23.PubMed
49.
Ohtani M, Kotaki H, Sawada Y, Iga T. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther. 1995;272(2):505–10.PubMed
50.
Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Decleves X. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010;13(7):905–15.PubMedCrossRef
51.
Alhaddad H, Cisternino S, Decleves X, Tournier N, Schlatter J, Chiadmi F, et al. Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice. Crit Care Med. 2012;40(12):3215–23.PubMedCrossRef
52.
Raehal KM, Walker JK, Bohn LM. Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther. 2005;314(3):1195–201.PubMedCrossRef
53.
Webster LR, Camilleri M, Finn A. Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals. Subst Abuse Rehabil. 2016;7:81–6.PubMedPubMedCentralCrossRef
54.
Brown SM, Holtzman M, Kim T, Kharasch ED. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology. 2011;115(6):1251–60.PubMedPubMedCentral
55.
Yassen A, Kan J, Olofsen E, Suidgeest E, Dahan A, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats. J Pharmacol Exp Ther. 2007;321(2):598–607.PubMedCrossRef
56.
Ohtani M, Kotaki H, Nishitateno K, Sawada Y, Iga T. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther. 1997;281(1):428–33.PubMed
57.
Strang J, Knight A, Baillie S, Reed K, Bogdanowicz K, Bell J. Norbuprenorphine and respiratory depression: Exploratory analyses with new lyophilized buprenorphine and sublingual buprenorphine. Int J Clin Pharmacol Ther. 2018;56(2):81–5.PubMedCrossRef
58.
Megarbane B, Marie N, Pirnay S, Borron SW, Gueye PN, Risede P, et al. Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol Appl Pharmacol. 2006;212(3):256–67.PubMedCrossRef
59.
Brown SM, Campbell SD, Crafford A, Regina KJ, Holtzman MJ, Kharasch ED. P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception. J Pharmacol Exp Ther. 2012;343(1):53–61.PubMedPubMedCentralCrossRef
60.
Wang Y, Cipriano A, Munera C, Harris SC. Dose-dependent flux of buprenorphine following transdermal administration in healthy subjects. J Clin Pharmacol. 2016;56(10):1263–71.PubMedCrossRef
61.
Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011;4(1):28–41.PubMedPubMedCentralCrossRef
62.
Bullingham RE, McQuay HJ, Moore RA. Clinical pharmacokinetics of narcotic agonist-antagonist drugs. Clin Pharmacokinet. 1983;8(4):332–43.PubMedCrossRef
63.
Mendelson J, Upton RA, Everhart ET, Jacob P 3rd, Jones RT. Bioavailability of sublingual buprenorphine. J Clin Pharmacol. 1997;37(1):31–7.PubMedCrossRef
64.
Nath RP, Upton RA, Everhart ET, Cheung P, Shwonek P, Jones RT, et al. Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol. 1999;39(6):619–23.PubMedCrossRef
65.
Downing JW, Leary WP, White ES. Buprenorphine: a new potent long-acting synthetic analgesic. Comparison with morphine. Br J Anaesth. 1977;49(3):251–5.PubMedCrossRef
66.
Yassen A, Olofsen E, Kan J, Dahan A, Danhof M. Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine. Clin Pharmacokinet. 2007;46(5):433–47.PubMedCrossRef
67.
Yassen A, Olofsen E, Dahan A, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther. 2005;313(3):1136–49.PubMedCrossRef
68.
Bullingham RE, McQuay HJ, Moore A, Bennett MR. Buprenorphine kinetics. Clin Pharmacol Ther. 1980;28(5):667–72.PubMedCrossRef
69.
Yassen A, Kan J, Olofsen E, Suidgeest E, Dahan A, Danhof M. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats. J Pharmacol Exp Ther. 2006;319(2):682–92.PubMedCrossRef
70.
Yassen A, Olofsen E, Romberg R, Sarton E, Danhof M, Dahan A. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology. 2006;104(6):1232–42.PubMedCrossRef
71.
Koppert W, Ihmsen H, Korber N, Wehrfritz A, Sittl R, Schmelz M, et al. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain. 2005;118(1–2):15–22.PubMedCrossRef
72.
Ebling WF, Lee EN, Stanski DR. Understanding pharmacokinetics and pharmacodynamics through computer stimulation: I. The comparative clinical profiles of fentanyl and alfentanil. Anesthesiology. 1990;72(4):650–8.PubMedCrossRef
73.
Pontani RB, Vadlamani NL, Misra AL. Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant. Xenobiotica. 1985;15(4):287–97.PubMedCrossRef
74.
Shiue CY, Bai LQ, Teng RR, Arnett CD, Dewey SL, Wolf AP, et al. A comparison of the brain uptake of N-(cyclopropyl[11C]methyl)norbuprenorphine ([11C]buprenorphine) and N-(cyclopropyl[11C]methyl)nordiprenorphine ([11C]diprenorphine) in baboon using PET. Int J Rad Appl Instrum B. 1991;18(3):281–8.PubMedCrossRef
75.
Greenwald M, Johanson CE, Bueller J, Chang Y, Moody DE, Kilbourn M, et al. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry. 2007;61(1):101–10.PubMedCrossRef
76.
Plosker GL. Buprenorphine 5, 10 and 20 mug/h transdermal patch: a review of its use in the management of chronic non-malignant pain. Drugs. 2011;71(18):2491–509.PubMedCrossRef
77.
Heel RC, Brogden RN, Speight TM, Avery GS. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs. 1979;17(2):81–110.PubMedCrossRef
78.
Brewster D, Humphrey MJ, McLeavy MA. Biliary excretion, metabolism and enterohepatic circulation of buprenorphine. Xenobiotica. 1981;11(3):189–96.PubMedCrossRef
79.
Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos. 1984;12(5):577–81.PubMed
80.
Picard N, Cresteil T, Djebli N, Marquet P. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005;33(5):689–95.PubMedCrossRef
81.
Sullivan JG, Webster L. Novel buccal film formulation of buprenorphine-naloxone for the maintenance treatment of opioid dependence: a 12-week conversion study. Clin Ther. 2015;37(5):1064–75.PubMedCrossRef
82.
Webster L, Hjelmstrom P, Sumner M, Gunderson EW. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: a randomized trial. J Addict Dis. 2016;35(4):325–38.PubMedCrossRef
83.
Kuhlman JJ Jr, Lalani S, Magluilo J Jr, Levine B, Darwin WD. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol. 1996;20(6):369–78.PubMedCrossRef
84.
Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44(7):661–80.PubMedCrossRef
85.
Gunderson EW, Hjelmstrom P, Sumner M, Study I. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial. Clin Ther. 2015;37(10):2244–55.
86.
Fischer A, Jonsson M, Hjelmstrom P. Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers. Drug Dev Ind Pharm. 2015;41(1):79–84.PubMedCrossRef
87.
Lintzeris N, Leung SY, Dunlop AJ, Larance B, White N, Rivas GR, et al. A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. Drug Alcohol Depend. 2013;131(1–2):119–26.PubMedCrossRef
88.
Bai SA, Xiang Q, Finn A. Evaluation of the pharmacokinetics of single- and multiple-dose buprenorphine buccal film in healthy volunteers. Clin Ther. 2016;38(2):358–69.PubMedCrossRef
89.
Priestley T, Chappa AK, Mould DR, Upton RN, Shusterman N, Passik S, et al. Converting from transdermal to buccal formulations of buprenorphine: a pharmacokinetic meta-model simulation in healthy volunteers. Pain Med. Epub 29 Sep 2017. https://​doi.​org/​10.​1093/​pm/​pnx235.
90.
Evans HC, Easthope SE. Transdermal buprenorphine. Drugs. 2003;63(19):1999–2010 (discussion 1–2).PubMedCrossRef
91.
Sittl R. Transdermal buprenorphine in the treatment of chronic pain. Expert Rev Neurother. 2005;5(3):315–23.PubMedCrossRef
92.
Kapil RP, Cipriano A, Friedman K, Michels G, Shet MS, Colucci SV, et al. Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels. J Pain Symp Manag. 2013;46(1):65–75.CrossRef
93.
Plosker GL, Lyseng-Williamson KA. Buprenorphine 5, 10 and 20 mug/h transdermal patch: a guide to its use in chronic non-malignant pain. CNS Drugs. 2012;26(4):367–73.PubMedCrossRef
94.
Middleton LS, Nuzzo PA, Lofwall MR, Moody DE, Walsh SL. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction. 2011;106(8):1460–73.PubMedPubMedCentralCrossRef
95.
Walsh SL, Nuzzo PA, Babalonis S, Casselton V, Lofwall MR. Intranasal buprenorphine alone and in combination with naloxone: abuse liability and reinforcing efficacy in physically dependent opioid abusers. Drug Alcohol Depend. 2016;162:190–8.PubMedPubMedCentralCrossRef
96.
Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet. 1999;37(1):17–40.PubMedCrossRef
97.
Chang Y, Moody DE. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab Lett. 2009;3(2):101–7.PubMedCrossRef
98.
Blanco F, Muriel C, Labrador J, Gonzalez-Porras JR, Gonzalez-Sarmiento R, Lozano FS. Influence of UGT2B7, CYP3A4, and OPRM1 gene polymorphisms on transdermal buprenorphine pain control in patients with critical lower limb ischemia awaiting revascularization. Pain Pract. 2016;16(7):842–9.PubMedCrossRef
99.
Sastre JA, Varela G, Lopez M, Muriel C, Gonzalez-Sarmiento R. Influence of uridine diphosphate-glucuronyltransferase 2B7 (UGT2B7) variants on postoperative buprenorphine analgesia. Pain Pract. 2015;15(1):22–30.PubMedCrossRef
100.
Moody DE, Slawson MH, Strain EC, Laycock JD, Spanbauer AC, Foltz RL. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem. 2002;306(1):31–9.PubMedCrossRef
101.
Fihlman M, Hemmila T, Hagelberg NM, Kuusniemi K, Backman JT, Laitila J, et al. Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction. Eur J Clin Pharmacol. 2016;72(11):1363–71.PubMedCrossRef
102.
Kapil RP, Cipriano A, Michels GH, Perrino P, O’Keefe SA, Shet MS, et al. Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system. Clin Drug Investig. 2012;32(9):583–92.PubMed
103.
Moody DE, Chang Y, Huang W, McCance-Katz EF. The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism. Basic Clin Pharmacol Toxicol. 2009;105(3):211–5.PubMedPubMedCentralCrossRef
104.
Moody DE, Fang WB, Lin SN, Weyant DM, Strom SC, Omiecinski CJ. Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes. Drug Metab Dispos. 2009;37(12):2323–9.PubMedPubMedCentralCrossRef
105.
Mahmood I. Prediction of clearance, volume of distribution, and half-life of drugs in extremely low to low birth weight neonates: an allometric approach. Eur J Drug Metab Pharmacokinet. 2017;42(4):601–10.PubMedCrossRef
106.
Ng CM, Dombrowsky E, Lin H, Erlich ME, Moody DE, Barrett JS, et al. Population pharmacokinetic model of sublingual buprenorphine in neonatal abstinence syndrome. Pharmacotherapy. 2015;35(7):670–80.PubMedPubMedCentralCrossRef
107.
Vest M. Insufficient glucuronide formation in the newborn and its relationship to the pathogenesis of icterus neonatorum. Arch Dis Child. 1958;33(171):473–6.PubMedPubMedCentralCrossRef
108.
Choonara I, Lawrence A, Michalkiewicz A, Bowhay A, Ratcliffe J. Morphine metabolism in neonates and infants. Br J Clin Pharmacol. 1992;34(5):434–7.PubMedPubMedCentralCrossRef
109.
de Wildt SN, Kearns GL, Murry DJ, Koren G, van den Anker JN. Ontogeny of midazolam glucuronidation in preterm infants. Eur J Clin Pharmacol. 2010;66(2):165–70.PubMedCrossRef
110.
Hartley R, Green M, Quinn MW, Rushforth JA, Levene MI. Development of morphine glucuronidation in premature neonates. Biol Neonate. 1994;66(1):1–9.PubMedCrossRef
111.
Michel E, Anderson BJ, Zernikow B. Buprenorphine TTS for children: a review of the drug’s clinical pharmacology. Paediatr Anaesth. 2011;21(3):280–90.PubMedCrossRef
112.
Michel E, Zernikow B. Buprenorphine in children. A clinical and pharmacological review [in German]. Schmerz. 2006;20(1):40–50.PubMedCrossRef
113.
Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8(4):287–313.PubMedCrossRef
114.
115.
Al-Tawil N, Odar-Cederlof I, Berggren AC, Johnson HE, Persson J. Pharmacokinetics of transdermal buprenorphine patch in the elderly. Eur J Clin Pharmacol. 2013;69(2):143–9.PubMedCrossRef
116.
Filitz J, Griessinger N, Sittl R, Likar R, Schuttler J, Koppert W. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain. 2006;10(8):743–8.PubMedCrossRef
117.
Boger RH. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. Palliat Med. 2006;20(Suppl 1):s17–23.PubMed
118.
Yeung CK, Shen DD, Thummel KE, Himmelfarb J. Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int. 2014;85(3):522–8.PubMedCrossRef
119.
Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol. 2006;17(9):2363–7.PubMedCrossRef
120.
Hand CW, Sear JW, Uppington J, Ball MJ, McQuay HJ, Moore RA. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth. 1990;64(3):276–82.PubMedCrossRef
121.
Summerfield RJ, Allen MC, Moore RA, Sear JW, McQuay HJ. Buprenorphine in end stage renal failure. Anaesthesia. 1985;40(9):914.PubMedCrossRef
122.
Nasser AF, Heidbreder C, Liu Y, Fudala PJ. Pharmacokinetics of sublingual buprenorphine and naloxone in subjects with mild to severe hepatic impairment (child-pugh classes A, B, and C), in hepatitis C virus-seropositive subjects, and in healthy volunteers. Clin Pharmacokinet. 2015;54(8):837–49.PubMedCrossRef
123.
Furlan V, Demirdjian S, Bourdon O, Magdalou J, Taburet AM. Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers. J Pharmacol Exp Ther. 1999;289(2):1169–75.PubMed
124.
Hardwick RN, Ferreira DW, More VR, Lake AD, Lu Z, Manautou JE, et al. Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos. 2013;41(3):554–61.PubMedPubMedCentralCrossRef
125.
Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–61.PubMedCrossRef
126.
Elbekai RH, Korashy HM, El-Kadi AO. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab. 2004;5(2):157–67.PubMedCrossRef
127.
Ciccozzi A, Angeletti C, Baldascino G, Petrucci E, Bonetti C, De Santis S, et al. High dose of buprenorphine in terminally ill patient with liver failure: efficacy and tolerability. J Opioid Manag. 2012;8(4):253–9.PubMedCrossRef
128.
Wolff RF, Aune D, Truyers C, Hernandez AV, Misso K, Riemsma R, et al. Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. Curr Med Res Opin. 2012;28(5):833–45.PubMedCrossRef
129.
Wolff RF, Reid K, di Nisio M, Aune D, Truyers C, Hernandez AV, et al. Systematic review of adverse events of buprenorphine patch versus fentanyl patch in patients with chronic moderate-to-severe pain. Pain Manag. 2012;2(4):351–62.PubMedCrossRef
130.
Ahn JS, Lin J, Ogawa S, Yuan C, O’Brien T, Le BH, et al. Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review. J Pain Res. 2017;10:1963–72.PubMedPubMedCentralCrossRef
131.
Cote J, Montgomery L. Sublingual buprenorphine as an analgesic in chronic pain: a systematic review. Pain Med. 2014;15(7):1171–8.PubMedCrossRef
132.
James IG, O’Brien CM, McDonald CJ. A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain. J Pain Symp Manag. 2010;40(2):266–78.CrossRef
133.
134.
Wiffen PJ, Derry S, Moore RA, Stannard C, Aldington D, Cole P, et al. Buprenorphine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;(9):CD011603.
135.
Buprenorphine for chronic pain: a review of the clinical effectiveness. Ottawa (ON); Canadian Agency for Drugs and Technologies in Health; 2017.
136.
Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2003;25(1):150–68.PubMedCrossRef
137.
Poulain P, Denier W, Douma J, Hoerauf K, Samija M, Sopata M, et al. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. J Pain Symp Manag. 2008;36(2):117–25.CrossRef
138.
Conaghan PG, O’Brien CM, Wilson M, Schofield JP. Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial. Osteoarthritis Cartilage. 2011;19(8):930–8.PubMedCrossRef
139.
Steiner D, Munera C, Hale M, Ripa S, Landau C. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. J Pain. 2011;12(11):1163–73.PubMedCrossRef
140.
Steiner DJ, Sitar S, Wen W, Sawyerr G, Munera C, Ripa SR, et al. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naive patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. J Pain Symptom Manag. 2011;42(6):903–17.CrossRef
141.
Landau CJ, Carr WD, Razzetti AJ, Sessler NE, Munera C, Ripa SR. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study. Clin Ther. 2007;29(10):2179–93.PubMedCrossRef
142.
Gordon A, Callaghan D, Spink D, Cloutier C, Dzongowski P, O’Mahony W, et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther. 2010;32(5):844–60.PubMedCrossRef
143.
Mitra F, Chowdhury S, Shelley M, Williams G. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. Pain Med. 2013;14(1):75–83.PubMedCrossRef
144.
Muriel C, Failde I, Mico JA, Neira M, Sanchez-Magro I. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. Clin Ther. 2005;27(4):451–62.PubMedCrossRef
145.
Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice—a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin. 2005;21(8):1147–56.PubMedCrossRef
146.
Gianni W, Madaio AR, Ceci M, Benincasa E, Conati G, Franchi F, et al. Transdermal buprenorphine for the treatment of chronic noncancer pain in the oldest old. J Pain Symptom Manag. 2011;41(4):707–14.CrossRef
147.
Sittl R, Nuijten M, Poulsen Nautrup B. Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany. Clin Ther. 2006;28(8):1144–54.PubMedCrossRef
148.
Likar R, Kayser H, Sittl R. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clin Ther. 2006;28(6):943–52.PubMedCrossRef
149.
Aalto M, Visapaa JP, Halme JT, Fabritius C, Salaspuro M. Effectiveness of buprenorphine maintenance treatment as compared to a syringe exchange program among buprenorphine misusing opioid-dependent patients. Nord J Psychiatry. 2011;65(4):238–43.PubMedCrossRef
150.
Yoon DH, Bin SI, Chan SK, Chung CK, In Y, Kim H, et al. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain. BMC Musculoskelet Disord. 2017;18(1):337.PubMedPubMedCentralCrossRef
151.
Lesen E, Ericson L, Simonsberg C, Varelius R, Bjorholt I, Soderpalm B. Dose patterns among patients using low-dose buprenorphine patches. Pain Med. 2013;14(9):1374–80.PubMedCrossRef
152.
Rauck RL, Potts J, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain. Postgrad Med. 2016;128(1):1–11.PubMedCrossRef
153.
Gimbel J, Spierings EL, Katz N, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study. Pain. 2016;157(11):2517–26.PubMedPubMedCentralCrossRef
154.
Hale M, Urdaneta V, Kirby MT, Xiang Q, Rauck R. Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids. J Pain Res. 2017;10:233–40.PubMedPubMedCentralCrossRef
155.
Przeklasa-Muszynska A, Dobrogowski J. Transdermal buprenorphine in the treatment of cancer and non-cancer pain—the results of multicenter studies in Poland. Pharmacol Rep. 2011;63(4):935–48.PubMedCrossRef
156.
Budd K. High dose buprenorphine for postoperative analgesia. Anaesthesia. 1981;36(9):900–3.PubMedCrossRef
157.
Kim HJ, Ahn HS, Nam Y, Chang BS, Lee CK, Yeom JS. Comparative study of the efficacy of transdermal buprenorphine patches and prolonged-release tramadol tablets for postoperative pain control after spinal fusion surgery: a prospective, randomized controlled non-inferiority trial. Eur Spine J. 2017;26(11):2961–8.PubMedCrossRef
158.
Mercieri M, Palmisani S, De Blasi RA, D’Andrilli A, Naccarato A, Silvestri B, et al. Low-dose buprenorphine infusion to prevent postoperative hyperalgesia in patients undergoing major lung surgery and remifentanil infusion: a double-blind, randomized, active-controlled trial. Br J Anaesth. 2017;119(4):792–802.PubMedCrossRef
159.
Chang KY, Chang WK, Chang WL, Lin SM, Chan KH, Sung CS, et al. Comparison of intravenous patient-controlled analgesia with buprenorphine versus morphine after lumbar spinal fusion—a prospective randomized clinical trial. Acta Anaesthesiol Taiwan. 2006;44(3):153–9.PubMed
160.
Williams BA, Butt MT, Zeller JR, Coffee S, Pippi MA. Multimodal perineural analgesia with combined bupivacaine-clonidine-buprenorphine-dexamethasone: safe in vivo and chemically compatible in solution. Pain Med. 2015;16(1):186–98.PubMedCrossRef
161.
Alemanno F, Westermann B, Bettoni A, Candiani A, Cesana BM. Buprenorphine versus tramadol as perineural adjuvants for postoperative analgesia in patients undergoing arthroscopic rotator cuff repair under middle interscalene block: a retrospective study. Minerva Anestesiol. 2014;80(11):1198–204.PubMed
162.
Kosel J, Bobik P, Tomczyk M. Buprenorphine: the unique opioid adjuvant in regional anesthesia. Expert Rev Clin Pharmacol. 2016;9(3):375–83.PubMedCrossRef
163.
Strain EC, Moody DE, Stoller KB, Walsh SL, Bigelow GE. Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend. 2004;74(1):37–43.PubMedCrossRef
164.
Weinhold LL, Bigelow GE, Preston KL. Combination of naloxone with buprenorphine in humans. NIDA Res Monogr. 1989;95:485.PubMed
165.
Simojoki K, Vorma H, Alho H. A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone). Subst Abuse Treat Prev Policy. 2008;3:16.PubMedPubMedCentralCrossRef
166.
Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 1997;25(1):1–4.PubMed
167.
Sittl R, Likar R, Nautrup BP. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther. 2005;27(2):225–37.PubMedCrossRef
168.
Mok MS, Lippmann M, Steen SN. Multidose/observational, comparative clinical analgetic evaluation of buprenorphine. J Clin Pharmacol. 1981;21(7):323–9.PubMedCrossRef
169.
Tigerstedt I, Turunen M, Tammisto T, Hastbacka J. The effect of buprenorphine and oxycodone on the intracholedochal passage pressure. Acta Anaesthesiol Scand. 1981;25(2):99–102.PubMedCrossRef
170.
Wang RI, Johnson RP, Robinson N, Waite E. The study of analgesics following single and repeated doses. J Clin Pharmacol. 1981;21(2):121–5.PubMedCrossRef
171.
Mercadante S, Casuccio A, Tirelli W, Giarratano A. Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Support Care Cancer. 2009;17(6):715–8.PubMedCrossRef
172.
Mercadante S, Porzio G, Fulfaro F, Aielli F, Verna L, Ficorella C, et al. Switching from transdermal drugs: an observational “N of 1” study of fentanyl and buprenorphine. J Pain Symptom Manage. 2007;34(5):532–8.PubMedCrossRef
173.
Cuschieri RJ, Morran CG, McArdle CS. Comparison of morphine and sublingual buprenorphine following abdominal surgery. Br J Anaesth. 1984;56(8):855–9.PubMedCrossRef
174.
Skaer TL. Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain. J Pain Res. 2014;7:495–503.PubMedPubMedCentralCrossRef
175.
Oifa S, Sydoruk T, White I, Ekstein MP, Marouani N, Chazan S, et al. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery. Clin Ther. 2009;31(3):527–41.PubMedCrossRef
176.
Mercadante S, Villari P, Ferrera P, Porzio G, Aielli F, Verna L, et al. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symp Manag. 2006;32(2):175–9.CrossRef
177.
Stromer W, Michaeli K, Sandner-Kiesling A. Reply to: an alternative way of managing acute pain in patients who are in buprenorphine opioid substitution therapy programmes. Eur J Anaesthesiol. 2013;30(11):718–9.PubMedCrossRef
178.
Stromer W, Michaeli K, Sandner-Kiesling A. Perioperative pain therapy in opioid abuse. Eur J Anaesthesiol. 2013;30(2):55–64.PubMedCrossRef
179.
Huxtable CA, Macintyre PE. An alternative way of managing acute pain in patients who are in buprenorphine opioid substitution therapy programs. Eur J Anaesthesiol. 2013;30(11):717–8.PubMedCrossRef
180.
Leighton BL, Crock LW. Case series of successful postoperative pain management in buprenorphine maintenance therapy patients. Anesth Analg. 2017;125(5):1779–83.PubMedPubMedCentralCrossRef
181.
Rosado J, Walsh SL, Bigelow GE, Strain EC. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100 mg of daily methadone. Drug Alcohol Depend. 2007;90(2–3):261–9.PubMedPubMedCentralCrossRef
182.
Malinoff HL, Barkin RL, Wilson G. Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther. 2005;12(5):379–84.PubMedCrossRef
183.
Rosenblum A, Cruciani RA, Strain EC, Cleland CM, Joseph H, Magura S, et al. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol. J Opioid Manag. 2012;8(6):369–82.PubMedPubMedCentralCrossRef
184.
Daitch D, Daitch J, Novinson D, Frey M, Mitnick C, Pergolizzi J Jr. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. Pain Med. 2014;15(12):2087–94.PubMedCrossRef
185.
Daitch J, Frey ME, Silver D, Mitnick C, Daitch D, Pergolizzi J, Jr. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. Pain Physician. 2012;15(3 Suppl):ES59–66.
186.
Webster L, Gruener D, Kirby T, Xiang Q, Tzanis E, Finn A. Evaluation of the tolerability of switching patients on chronic full mu-opioid agonist therapy to buccal buprenorphine. Pain Med (Epub 25 Feb 2016).
187.
188.
Boyer EW, McCance-Katz EF, Marcus S. Methadone and buprenorphine toxicity in children. Am J Addict. 2010;19(1):89–95.PubMedCrossRef
189.
Fareed A, Patil D, Scheinberg K, Blackinton Gale R, Vayalapalli S, Casarella J, et al. Comparison of QTc interval prolongation for patients in methadone versus buprenorphine maintenance treatment: a 5-year follow-up. J Addict Dis. 2013;32(3):244–51.PubMedCrossRef
190.
Stallvik M, Nordstrand B, Kristensen O, Bathen J, Skogvoll E, Spigset O. Corrected QT interval during treatment with methadone and buprenorphine: relation to doses and serum concentrations. Drug Alcohol Depend. 2013;129(1–2):88–93.PubMedCrossRef
191.
de Jong IM, de Ruiter GS. Buprenorphine as a safe alternative to methadone in a patient with acquired long QT syndrome: a case report. Neth Heart J. 2013;21(5):249–52.PubMedCrossRef
192.
Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 2007;167(22):2469–75.PubMedCrossRef
193.
Krantz MJ, Garcia JA, Mehler PS. Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. Pharmacotherapy. 2005;25(4):611–4.PubMedCrossRef
194.
Darpo B, Zhou M, Bai SA, Ferber G, Xiang Q, Finn A. Differentiating the effect of an opioid agonist on cardiac repolarization from micro-receptor-mediated, indirect effects on the qt interval: a randomized, 3-way crossover study in healthy subjects. Clin Ther. 2016;38(2):315–26.PubMedCrossRef
195.
Harris SC, Morganroth J, Ripa SR, Thorn MD, Colucci S. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials. Postgrad Med. 2017;129(1):69–80.PubMedCrossRef
196.
Mayet S, Gossop M, Lintzeris N, Markides V, Strang J. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation? Drug Alcohol Rev. 2011;30(4):388–96.PubMedCrossRef
197.
Russell L, Levine D. Methadone-induced Torsades de pointes. R I Med J (2013). 2013;96(8):20–1.
198.
Baker JR, Best AM, Pade PA, McCance-Katz EF. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann Pharmacother. 2006;40(3):392–6.PubMedCrossRef
199.
Kao DP, Haigney MC, Mehler PS, Krantz MJ. Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration. Addiction. 2015;110(9):1468–75.PubMedPubMedCentralCrossRef
Metadaten
Titel
Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option
verfasst von
Mellar P. Davis
Gavril Pasternak
Bertrand Behm
Publikationsdatum
01.08.2018
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 12/2018
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-018-0953-z

Weitere Artikel der Ausgabe 12/2018

Drugs 12/2018 Zur Ausgabe

Adis Drug Evaluation

Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections

Correction

Correction to: Anlotinib: First Global Approval

AdisInsight Report

Encorafenib and Binimetinib: First Global Approvals

Leading Article

Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease

Review Article

Perioperative Use of Intravenous Lidocaine

Correction

Correction to: Andexanet Alfa: First Global Approval